AMGEN to pay about $125/ share for ONYX with patent for multiple myeloma drug.
This 1 drug is expected to bring in sales of $3 Billion.
Imagine what ONCY could be worth with a treatment for 10 different cancers.
$125 x 10 = $1250./ share.
We just have to watch & wait for next round of trial results.
At 12:10 today on level 11 trading screen I see a bid of 291,000 shares bid at $1.64 / share.
Who is trying to buy a big block of shares at this low price?
Whoever it is has lots of resources. Big Pharma ? Buy out Biggie?
A big Fund? A big Bank ? A foreign investor? Warren Buffet ?
On second thought it is only about a half million dollar investment .
It could even be the guy next door.
I believe ONCY lost control of the testing at all these different test sites.
Reo test patients dropped out when they got fevers( to be treated for fevers.)
Chemo control patients dropped out because the chemo wasnt working to try other treatments.
25% of patients dropped out.
Being double blinded & out of communication & control 0f these patients was an unforseen
problem . Results of patients that dropped out are not comparable to anything.
In spite of this problem the results of the patients that stayed in the testing showed very good results for REO.
The next round of testing will confirm it.
The question is should Brad move ahead on Pancreatic or Lung ahead of H&N as first line treatment?
ONCY may be down but it is far from out.
Who bought 6,350,768 shares of ONCY on Nov 21st ?
Who bought 3,005,682 shares of ONCY on Nov 22 nd ?
Who bought 18,000 shares after hours Fri Night ?
Thats a lot of buys ........... at bargain prices.
Do you think a large drug company was starting to buy?
If the trial participants are still alive -- thats a good sign & not bad.
That means that the REO participants are still alive. Thats good.
If some of the CHEMO ONLY participants are still hanging on .........
past experience shows this is just temporary.
After the holidays many terminal patients tend to give up after hanging on for a long time.
I believe December 2-3 will be the unbinding date.
21 blocks of ONCY stock purchased today of 1,000 shares or more.
Is this the shorts still buying to cover or did they already cover & they are buying in for the ride up?
Why the big cover now & not a month ago? What do they know that we dont ?
What did ONCY mean when they said this on 9/10/12?
We intend to treat this expanded 1 st stage of REO 018 clinical trial as a separate supportive study to a planned registration study that will be similar to, & take the place of, the original second stage of REO 018 clinical trial.
The company intends to submit protocol amendments to regulators in the immediate near term to reflect these changes.
In REO 016 Lung Cancer Study Brad said:
66.6 % of REO Patients survived more than 1 year with EGFR mutations or amplification.
69.2 % of REO patients survived more than 1 year with EGFR mutations
100% of REO Patients survived more than 1 year with
This proves REO is highly effective in patients with these biomarkers.
By prescreening these patients good outcomes can be predictive.
How many shares do you own?
Between them their companies own millions of shares of ONCY.
Brad said that useing Biomarkers they can predict the outcome of Cancer trials.
Utilizing this knowledge ONCY can predict who will survive & who will not in future REO trials.
Translation : With prescreening ONCY can have dynamite results in REO trial testing compared to poor results of Chemo.
He underscored " Exciting New Data."
The following heavy hitters in Biotech Investment Community asked tough , Knowledgeable & relavant questions .
Allen Ridgeway Paradyme Capital
Boris Peakin Oppenheimer
Neil Canuka Canacord Genuity
Brian Klein Steisel
Philipa Flint Blomberg
18,300 shares bid at @2.86/ share. (11AM)
They want those shares badly.
First they sell shares cheap to get the price down & then they offer to buy large amounts of stock at those cheap prices.
As soon as buyers come in they pull their sell orders to sell.
They do this over & over again .
With such a low float & small amount of shares traded they get away with this stock manipulation.
With no manipulation the stock should be $4/ share now.
When they pulled their sell orders on the good Lung Trial results it shot up to $3.39/ share.
Its frustrating to watch .
It is my understanding that the original tumor develops a hard crust around it that is hard for REO to penetrate but by adding the chemo it opens the tumor for REO to enter & destroy it.
Also the metastatic tumors dont have that hard crust & as long as they are in the RAS PATHWAY REO can find them & penetrate & destroy them without the chemo. That is why REO is so effective against Metastatic tumors.
Also there is the later effect long after REO is not being used where the immune system recognizes the tumor & destroys it. I dont think this effect is so well understood.
Recently saw one of the pioneers of Tarceva at Cold Sring Harbour Labs. (in Long Island ,N.Y.)
She said that Tarceva works for only 1 year for lung cancer control & then stops working on most
lung cancer patients. She went there to do research on why it stops working. (They won 8 Nobel Prizes
in medicine there).
I see REO taking over for Tarceva in near future . With the high lung cancer death rate it would be foolish for the FDA to not approve it on fast track.
Biotech drug from Roche( Perjeta) just received accelerated approval by the FDA.
As a condition of approval Roche must conduct a larger follow up study showing the drugs long term benefits for patients.
The new drug is approved for use before surgery based on the fact that it keeps patients cancer free for 12 weeks longer than chemo.
Based on the above criteria REO should be fast track approved by the FDA .We all know that REO patients keep on living & living.
Imagine if REO were given to newly diagnosed patients instead of stage 4 patients.
REO induces tumor cell lysis through selective replication & activates T CELLS for a specific systemic immune response. And that says a lot.